LifeVantage Corporation

LifeVantage Corporation (LFVN) Market Cap

LifeVantage Corporation has a market capitalization of $119.6M.

Price: $9.48

-0.02 (-0.21%)

Market Cap: 119.60M

NASDAQ · time unavailable

CEO: Carl A. Aure

Sector: Consumer Defensive

Industry: Packaged Foods

IPO Date: 1994-04-07

Website: https://www.lifevantage.com

LifeVantage Corporation (LFVN) - Company Information

Market Cap: 119.60M|Sector: Consumer Defensive

Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. LifeVantage Corporation is headquartered in Lehi, Utah.

Analyst Sentiment

46%
Hold

From 3 Active Polls

1Y Forecast: $5.00

▼ -47.3% Potential Upside

Consensus Target Metrics

Low Bound

$5

Median

$5

High Bound

$5

Average

$5

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$5.00
▼ -47.26% Upside
Low Target
$5.00
-47% Risk
Median Target
$5.00
-47% Mid
High Target
$5.00
-47% Max
Consensus
Hold
1 / 3 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)120557812116118021414777
Enterprise Value ($M)117527811915217121314674
Price to Earnings Ratio (P/E)20.8110.0170.5413.9920.5712.9720.9920.1114.83
Price/Earnings-to-Growth Ratio (PEG)24.490.4810.43
Price to Sales Ratio (P/S)0.611.251.592.542.933.083.163.111.58
Price to Book Ratio (P/B)3.591.642.363.645.396.027.735.302.98
Price to Free Cash Flow Ratio (P/FCF)31.6813.7145.62-43.96193.0894.9224.58-157.6433.61
Enterprise Value to Sales (EV/Sales)1.201.602.502.772.933.143.091.52
Enterprise Value to EBITDA (EV/EBITDA)12.4721.8563.2741.2652.5935.2650.2743.2719.96
Debt to Equity Ratio-0.240.310.320.340.430.430.480.480.52

LFVN Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$9.48
Intrinsic Value$5.35
Market Alignment
Overvalued by 43.6%relative to calculated intrinsic value
9.00%
Exp: 1%1%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.01B
Perpetuity TV Value$0.20B
Discounted TV (PV)$0.08B
TV Weighting %58.0%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 LIFEVANTAGE CORP (LFVN) — Investment Overview

🧩 Business Model Overview

LIFEVANTAGE CORP is a wellness and personal-care direct-to-consumer distributor model. The company develops (or sources through proprietary ingredient work), markets, and sells a portfolio of dietary supplements and topical/personal-care products through independent distributors. The economic engine is a two-sided distribution system: customer demand is generated through distributor channels, while the distributor base is maintained and expanded through incentives tied to sales activity. This structure creates a recurring commercial workflow—product marketing, customer ordering, and distributor recruitment/activation—rather than a single, one-time retail transaction.

💰 Revenue Streams & Monetisation Model

Revenue is primarily product sales, monetized through distributor-driven ordering. Monetisation typically reflects:

  • Repeat consumption economics: wellness products are often repurchased, supporting a more stable demand pattern than purely seasonal goods.
  • Channel-driven margin structure: gross margin depends on product mix, ingredient/input costs, and manufacturing/fulfillment arrangements; operating margin depends on distributor incentives, customer acquisition support, and marketing spend.
  • Program economics: distributor compensation (commissions, incentives, and qualification rewards) scales with sales volume, making operating leverage more favorable when distributor productivity and retention remain healthy.

Overall, the business tends to monetize through volume and product-mix discipline rather than high recurring SaaS-like contract economics.

🧠 Competitive Advantages & Market Positioning

The moat is less about product switching barriers (consumer switching costs are generally low) and more about the durability of the distribution network and proprietary product differentiation.

  • Network effects (distributor-driven): increased distributor participation can improve local market penetration, product education, and social proof loops, which can raise conversion and reorder rates.
  • Intangible assets (proprietary formulations and product-specific IP/trademarks): product differentiation—enabled by proprietary blends and brand-owned intellectual property—can reduce direct comparability versus generic supplements.
  • Program switching via personal relationships: while consumers can technically switch brands easily, purchasing is often routed through a personal distributor relationship, which can slow churn versus purely ecommerce-led competitors.

Competitive benchmarking (primary competitors):

  • Herbalife — primarily nutrition and weight-management positioning with a global MLM/distributor base.
  • Nu Skin — personal care and age-management oriented direct-sales model.
  • Amway — broad wellness and consumer goods distribution with a mature direct-sales franchise.

Industry focus contrast: LIFEVANTAGE is positioned around targeted wellness and personal-care categories delivered through an independent distributor network. Versus Herbalife’s nutrition/weight-centric emphasis and Nu Skin’s stronger focus on age-related personal care, LIFEVANTAGE’s differentiation is tied to its own product portfolio and distributor enablement approach, which aims to create a cohesive “product + education + community” funnel.

🚀 Multi-Year Growth Drivers

Sustainable growth over a 5–10 year horizon is most likely tied to secular and structural tailwinds that support wellness consumption and distribution network scaling:

  • Secular demand for wellness: ongoing consumer preference for preventive health, functional nutrition, and topical self-care supports category durability.
  • Distributor productivity and retention: long-run growth depends on sustaining distributor activation, reducing churn, and improving sales per active distributor.
  • Geographic and channel expansion: scaling within underpenetrated markets and strengthening digital ordering/education can expand addressable demand without proportional increases in fixed costs.
  • Product-mix optimization: growth can be accelerated by emphasizing higher-margin SKUs and bundling strategies that raise repeat purchase rates.

⚠ Risk Factors to Monitor

  • Regulatory and compliance risk: wellness/supplement claims are subject to scrutiny; missteps can trigger enforcement actions, distributor remediation, or product scope changes.
  • Direct-sales execution risk: the model is sensitive to distributor recruitment and retention; sustained declines in active distributor counts can compress revenue and increase per-unit selling costs.
  • Competitive intensity: MLM wellness and supplement companies compete on pricing, education, and product novelty; product commoditization can pressure margins.
  • Supply chain and input cost volatility: ingredient procurement and contract manufacturing terms can move gross margin.
  • Capital and operating leverage: marketing/distributor incentives may rise to defend share; if productivity does not improve, fixed-cost absorption can weaken profitability.

📊 Valuation & Market View

Markets typically value direct-to-consumer wellness and distributor models through a mix of EV/EBITDA (for profitability durability) and P/S (for growth and cash-generation expectations). Key valuation drivers in this sector include:

  • Gross margin sustainability driven by product mix and input cost control.
  • Distributor productivity (sales per active distributor) and retention/activation that supports revenue stability.
  • Operating discipline in distributor incentives, marketing spend, and fulfillment efficiency.

🔍 Investment Takeaway

LIFEVANTAGE’s long-term investment case rests on a distributor-network business model with partial moats from distributor-driven network effects, proprietary product differentiation, and personal-relationship switching friction. Upside is most likely when distributor productivity and repeat consumption strengthen while margin and compliance remain stable. The primary watch items are regulatory posture and the durability of the active distributor base—both of which directly determine revenue quality and profitability over a full cycle.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for LFVN.

zacks.com2026-05-27

Do Options Traders Know Something About LifeVantage Stock We Don't?

Investors need to pay close attention to LFVN stock based on the movements in the options market lately.

seekingalpha.com2026-05-06

LifeVantage Corporation (LFVN) Q3 2026 Earnings Call Transcript

LifeVantage Corporation (LFVN) Q3 2026 Earnings Call Transcript

zacks.com2026-05-06

Lifevantage (LFVN) Q3 Earnings and Revenues Miss Estimates

Lifevantage (LFVN) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.26 per share a year ago.

globenewswire.com2026-05-06

LifeVantage Declares Quarterly Dividend

SALT LAKE CITY, May 06, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.050 per share of common stock, which will be paid June 15, 2026 to all stockholders of record at the close of business on June 1, 2026. About LifeVantage Corporation LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within.

globenewswire.com2026-05-06

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2026

SALT LAKE CITY, May 06, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2026. Third Quarter Fiscal 2026 Summary*: Revenue was $43.7 million, a decrease of 25.2% from the prior year period; Revenue in the Americas decreased 28.9%, and revenue in Asia/Pacific & Europe decreased 7.7%; Net income per diluted share was $0.11, versus $0.26 per diluted share a year ago; Adjusted earnings per diluted share was $0.12, compared to $0.26 a year ago; and Adjusted EBITDA was $3.2 million compared to $6.4 million a year ago.

zacks.com2026-04-28

Strength Seen in Lifevantage (LFVN): Can Its 8.5% Jump Turn into More Strength?

Lifevantage (LFVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

defenseworld.net2026-04-24

Lifevantage (NASDAQ:LFVN) Share Price Crosses Below 200-Day Moving Average – What’s Next?

Lifevantage Corporation (NASDAQ: LFVN - Get Free Report) passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $6.04 and traded as low as $4.71. Lifevantage shares last traded at $4.96, with a volume of 923,481 shares traded. Wall Street Analysts Forecast Growth A number of equities

globenewswire.com2026-04-22

LifeVantage to Announce Third Quarter Fiscal Year 2026 Results on May 6, 2026

SALT LAKE CITY, April 22, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its third quarter ended March 31, 2026, after the stock market closes on Wednesday, May 6, 2026. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.

globenewswire.com2026-04-21

LifeVantage Receives U.S. Patent for Healthy Glow Essentials Stack

SALT LAKE CITY, April 21, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced it has been granted a United States Patent No. 12,589,067 B2, issued March 31, 2026, for nutritional supplement composition and methods for activating cellular signaling genes of its Healthy Glow Essentials Stack™ which contains key activators Protandim® Nrf2 Synergizer® and TrueScience®Liquid Collagen.

globenewswire.com2026-04-20

LifeVantage Inspires with ‘Breakthrough' Announcements at 2026 Momentum Academy in Las Vegas

SALT LAKE CITY, April 20, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, successfully concluded its three-day Momentum Academy event at Planet Hollywood Resort and Casino in Las Vegas, Nevada. Centered on the theme of “Breakthrough,” the event brought together LifeVantage independent Consultants from across the country for an immersive experience focused on education, connection, and business growth.

globenewswire.com2026-04-16

LifeVantage Appointing Terrence Moorehead as Chief Executive Officer

SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Terrence Moorehead as the Company's new President and Chief Executive Officer and as a member of the Board of Directors (the “Board”), effective August 5, 2026. Mr. Moorehead is expected to commence employment with LifeVantage following the completion of his contractual commitments with his prior employer.

defenseworld.net2026-04-16

Lifevantage (NASDAQ:LFVN) Shares Pass Below Two Hundred Day Moving Average – Here’s What Happened

Lifevantage Corporation (NASDAQ: LFVN - Get Free Report)'s share price crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $6.22 and traded as low as $4.08. Lifevantage shares last traded at $4.35, with a volume of 137,581 shares. Analysts Set New Price Targets A number of

globenewswire.com2026-04-09

LifeVantage to Participate in Water Tower Research Insights Conference on Wednesday, April 15, 2026

SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer, Kristen Cunningham, Chief Sales Officer, and Lisa Barnes, Vice President Research & Development and Regulatory, will participate in the upcoming Water Tower Research Insights Conference on Wednesday, April 15, 2026.

globenewswire.com2026-04-02

LifeVantage Announces Expansion of its European Footprint with Market Opening in Portugal

SALT LAKE CITY, April 02, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, announced today it will be expanding its products and business opportunity in Portugal, welcoming a new wave of purpose-driven entrepreneurs and wellness seekers to its growing international community. This expansion, planned for a May 2026 launch, marks the Company's continued partnership with its field leadership on international expansion and reinforces its commitment to delivering science-backed wellness solutions to consumers around the world.

globenewswire.com2026-03-16

LifeVantage to Participate in the Sidoti Small Cap Conference

SALT LAKE CITY, March 16, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer and Carl Aure, Chief Financial Officer will participate in the Sidoti Small Cap Conference, to be held March 18-19, 2026. Mr. Fife and Mr.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"LFVN reported Q3 2026 (ended 2026-03-31) revenue of $43.7M and net income of $1.36M (EPS $0.11). Revenue declined -10.7% QoQ (from $48.9M in 2025-12-31) and -25.3% YoY (from $58.4M in 2025-03-31). Net income also fell sharply QoQ (-50.7% from $0.276M) and YoY (-60.8% from $3.47M). Profitability contracted: net margin dropped to 3.1% from 0.6% QoQ and from 5.9% YoY; operating margin eased to 3.8% versus 1.0% QoQ, but well below 6.9% a year ago. Cash generation remains positive but volatile. Operating cash flow was $5.0M and free cash flow $4.0M in Q3 2026, versus $2.8M OCF and $1.7M FCF QoQ. Balance sheet resilience looks mixed: cash increased to $12.5M, but equity remains thin at $33.3M while retained earnings are deeply negative. The company repurchased shares ($2.44M) and paid dividends ($0.57M), supporting shareholder returns, though price momentum is weak with a -66.3% 1-year change. Revenue/Earnings-based metrics are provided above (company is not pre-revenue)."

Revenue Growth

Neutral

Revenue declined -10.7% QoQ (49.0M to 43.7M) and -25.3% YoY (58.4M to 43.7M), indicating deteriorating top-line momentum.

Profitability

Caution

Net income fell -50.7% QoQ and -60.8% YoY; net margin is 3.1% in the latest quarter versus 5.9% YoY, showing contraction over the year.

Cash Flow Quality

Neutral

Operating cash flow of $5.0M and free cash flow of $4.0M were both higher QoQ; dividends (~$0.57M) and buybacks (~$2.44M) continued, but earnings declined materially.

Leverage & Balance Sheet

Caution

Cash increased to $12.5M and net debt remains negative (~-$2.3M), but equity is limited ($33.3M) with deeply negative retained earnings, reducing resilience.

Shareholder Returns

Neutral

Capital returns were mixed: buybacks and dividends were positive, but market performance is poor with -66.3% 1-year price change and only modest recent stability.

Analyst Sentiment & Valuation

Caution

Consensus price target is $5 versus current price ~$4.78 (limited upside implied); valuation multiples remain elevated (P/E ~10x on latest earnings), while fundamentals have weakened.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

LFVN’s Q3 2026 results show meaningful contraction: revenue fell 25% YoY to $43.7M and adjusted EBITDA declined to 7.3% of revenue (down ~370 bps). Gross margin deteriorated (79% vs 81% prior-year) due to shipping/warehouse cost increases and higher inventory obsolescence-related expenses; commissions as a % of revenue improved ~130 bps, but deleverage in SG&A outweighed it. Management reiterated that FY2026 metrics should land near the lower end of guidance, attributing weakness to GLP-1 competitive dynamics and active-account/contributor declines, especially in the Americas. The main operational levers are Shopify-driven ecommerce modernization (roll into Q1 with staggered international rollout), continued investment in technology, and field renewal via the 12-month opt-in VIP bonus linked to leadership behaviors plus simplified incentive programs. Capital allocation remains shareholder-friendly (no debt, $12.5M cash, ongoing buybacks, dividend up 11%). Overall, the quarter is a reset/transition story with cautious forward confidence.

AI IconGrowth Catalysts

  • Momentum Academy in Las Vegas (leadership training theme: “breakthrough”) driving renewed consultant engagement
  • VIP bonus: first-ever 12-month volume growth incentive program for consultants (opt-in leadership behavior + growth goals)
  • Targeted re-focus of field on “stickiest products” (Protandim, Collagen, Healthy Glow) to reinforce business foundations

Business Development

  • LoveBiome acquisition (closed October 2025) contributing “LoveBiome” sales partially offsetting MINDBODY GLP-1 system declines
  • Shopify ecommerce platform rollout with revamped upgraded back-office system (implementation ramp to start later in 2026; staggered international rollout)
  • P84 (from LoveBiome) remains a core “hero” line; continued complementary products planned to support P84

AI IconFinancial Highlights

  • Net revenue: $43.7M, down 25.2% YoY vs $58.4M (Americas -28.9% to $34.3M; APAC/Europe -7.7% to $9.4M)
  • Gross profit percentage: 79% vs 81% prior-year period (bps not explicitly stated, but down 200 bps); drivers: shipping + warehouse expense increases and higher inventory obsolescence-related expense
  • Non-GAAP adjusted gross profit %: 79.4%; excluded $183k MINDBODY inventory allowance
  • Commissions & incentives: 43.5% of revenue vs 44.8% prior-year period (down 130 bps); company attributes change to incentive timing/magnitude and customer/consultant mix
  • SG&A: $13.9M or 31.7% of revenue vs $17.1M or 29.2% prior-year (higher as % of revenue due to lower sales volume)
  • Adjusted EBITDA: $3.2M or 7.3% of revenues vs $6.4M or 11% a year ago (down 370 bps); GAAP net income: $1.4M or $0.11/diluted vs $3.5M or $0.26
  • Tax: Q3 income tax expense $300k vs $700k prior-year; full-year effective tax rate guidance 18% to 20%
  • Cash: $5.5M cash from operations in first nine months 2026 vs $10.8M prior-year; Q3 discussion indicates ~$5M cash from ops in the recent quarter and expectation to be similar in Q4

AI IconCapital Funding

  • Share repurchases: 206k shares for ~$1.0M during the quarter; ~250k shares for ~$1.6M in first nine months
  • Remaining capacity: $59M remaining under $60M repurchase authorization as of March 31, 2026
  • Dividend: quarterly cash dividend $0.05/share (11% increase) paid 06/15/2026 to record holders 06/01/2026
  • Balance sheet: $12.5M cash at quarter end; no debt
  • LoveBiome transaction cash usage: $3.7M used in first nine months 2026 for closing

AI IconStrategy & Ops

  • Shopify implementation: “start launching Shopify later this year”; CFO guidance in Q&A indicates targeted rollout not fully by end of Q4 but rolling into Q1 with staggered international approach
  • CapEx: $2.5M first nine months 2026 vs $1.2M prior-year, driven by technology infrastructure including Shopify integration
  • CapEx run-rate discussion: likely consistent for next quarter or two; expected reduction once implementation is in place (after entering Q1 next fiscal year)
  • Consultant base approach: “foundational approach” and business simplification; VIP program designed to be opt-in and leadership-driven
  • New CEO transition: Terrence Moorhead appointed 04/16/2026; joins August (transition work managed by Kristen Cunningham and Carl Aure)

AI IconMarket Outlook

  • FY 2026 outlook updated: company expects revenue, adjusted EBITDA, and adjusted EPS to end “close to the lower end” of previously issued guidance range (no exact numeric guidance provided in transcript)
  • Cash from operations: management expects “similar amount” in Q4 as recent quarter (Q&A: approximately ~$5M cash from ops in March quarter, anticipating similar Q4)

AI IconRisks & Headwinds

  • Competitive dynamics in the GLP-1 market (explicitly cited as factor in updated guidance to lower end)
  • Decline in MINDBODY GLP-1 system sales and decrease in total active accounts (Americas consultant/active base pressure)
  • Higher shipping and warehouse expenses and higher inventory obsolescence-related expenses impacting gross margin
  • SG&A deleverage: SG&A increased as % of revenue due to reduced sales volume
  • Cash flow timing comparisons noted as unusual in earlier quarters, implying volatility despite ongoing cash generation expectations

Q&A: Analyst Interest

  • Cash flow durability: Analyst asked whether Q4 should be positive in cash from operations given March-quarter shortfall. Management replied Q4 should be similar to the recent ~$5M cash-from-ops quarter and cited unusual first-quarter timing differences, expecting the “current model” to keep generating cash going forward.
  • Share buyback cadence and authorization usage: Analyst requested an update on the $60M authorization, noting limited purchases in March. CFO stated repurchases in-quarter were ~$1M (just over 200k shares) and reaffirmed commitment to buy “opportunistically” over coming quarters as valuations/market conditions permit, referencing board approval.
  • Consultant count decline and field engine reset: Analyst highlighted Americas consultant sequential drop (32k to 30k) and asked what’s driving it and what’s changing. Management emphasized moving from “pop-and-drop” to foundational business reinforcement, simplified incentives, focus on stickiest products, and an opt-in VIP leadership program seen as driving engagement post-Vegas.

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the LFVN Q3 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for LFVN.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (LFVN)

© 2026 Stock Market Info — LifeVantage Corporation (LFVN) Financial Profile